伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

刘清杏; 陈小元; 朱朝晖

doi:10.12290/xhyxzz.2021-0764

伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

doi: 10.12290/xhyxzz.2021-0764

刘清杏^{1, 2},
陈小元^3, ,,
朱朝晖^{1, 2, ,}

1.
中国医学科学院北京协和医院核医学科核医学分子靶向诊疗北京市重点实验室核医学精准诊疗技术创新北京市国际科技合作基地，北京 100730
2.
中国医学科学院北京协和医院核医学科疑难重症及罕见病国家重点实验室，北京 100730
3.
新加坡国立大学杨潞龄医学院/工程学院，新加坡 119077

基金项目:

国家自然科学基金 81871392

首都卫生发展科研专项 2018-1-4011

中国医学科学院医学与健康科技创新工程 2021-I2M-1-016

中国医学科学院临床转化基金 2019XK320032

详细信息

通讯作者:
陈小元，E-mail：chen.shawn@nus.edu.sg

朱朝晖，E-mail：zhuzhh@pumch.cn

中图分类号: R445; R-1
计量
- 文章访问数: 665
- HTML全文浏览量: 171
- PDF下载量: 102
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-01
- 录用日期: 2021-12-29
- 网络出版日期: 2022-01-12
- 刊出日期: 2022-03-30

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

LIU Qingxing^{1, 2},
CHEN Xiaoyuan^{3
, ,},
ZHU Zhaohui^{1, 2
, ,}

1.
Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing International Science and Technology Cooperation Base of Nuclear Medicine Precision Diagnosis and Treatment Technology Innovation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
2.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
3.
Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore 119077

Funds:

National Natural Science Foundation of China 81871392

The Capital Health Development Scientific Research Project 2018-1-4011

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016

CAMS Clinical and Translational Medicine Research Fund 2019XK320032

More Information

Corresponding author: CHEN Xiaoyuan, E-mail: chen.shawn@nus.edu.sg; ZHU Zhaohui, E-mail: zhuzhh@pumch.cn

摘要

摘要: 肽受体放射性核素治疗(peptide receptor radionuclide therapy，PRRT)是利用放射性核素标记的多肽与肿瘤细胞表面受体进行特异性结合，从而发挥射线的辐射生物效应。近年来，如何进一步提高PRRT药物的疗效一直是国际研究热点。伊文思兰(Evans blue)可与血浆中的白蛋白可逆性结合，故将伊文思兰加入多肽结构可延长放射性药物在血液中的清除时间，改变药代动力学，提高PRRT疗效。本文将围绕伊文思兰改造多肽用于诊疗一体化的临床转化研究进行概述。
- 伊文思兰 /
- 多肽 /
- 肽受体放射性核素治疗 /
- 诊疗一体化 /
- 临床转化
Abstract: Peptide receptor radionuclide therapy (PRRT) specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells that overexpress specific receptors. In recent years, how to further improve the efficacy of radiotherapeutic drugs for PRRT has been an international research hotspot.The peptides with Evans blue motif, uses endogenous albumin as a reversible carrier to effectively extend the half-life in the blood and substantially increase targeted accumulation and retention within the tumor to achieve better efficacy. This review focuses on the clinical translational research of Evans blue modified peptides used for theranostics.
- Evans blue /
- peptides /
- peptide receptor radionuclide therapy /
- theranostics /
- clinical translation
注释:

作者贡献：刘清杏负责文献查阅及初稿撰写；陈小元、朱朝晖负责选题设计，指导论文修订。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

图 1 伊文思兰分子式

下载: 全尺寸图片幻灯片

参考文献(43)

[1]	Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics[J]. Front Immunol, 2014, 5: 682.
[2]	Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45: 1432-1456. doi: 10.1039/C5CS00158G
[3]	Evans HM, Schulemann W. The Action of Vital Stains Belonging to the Benzidine Group[J]. Science, 1914, 39: 443-454. doi: 10.1126/science.39.1004.443
[4]	Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system[J]. Am J Physiol, 1969, 216: 675-681. doi: 10.1152/ajplegacy.1969.216.3.675
[5]	Niu G, Lang L, Kiesewetter DO, et al. In Vivo Labeling of Serum Albumin for PET[J]. J Nucl Med, 2014, 55: 1150-1156. doi: 10.2967/jnumed.114.139642
[6]	Wang Y, Lang L, Huang P, et al. In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112: 208-213. doi: 10.1073/pnas.1414821112
[7]	Zhang J, Lang L, Zhu Z, et al. Clinical Translation of an Albumin-Binding PET Radiotracer ⁶⁸Ga-NEB[J]. J Nucl Med, 2015, 56: 1609-1614. doi: 10.2967/jnumed.115.159640
[8]	Zang J, Liu Q, Sui H, et al. Combined (68)Ga-NOTA-Evans Blue Lymphoscintigraphy and (68)Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients[J]. Bioconjug Chem, 2020, 31: 396-403. doi: 10.1021/acs.bioconjchem.9b00789
[9]	Long X, Zhang J, Zhang D, et al. Microsurgery guided by sequential preoperative lymphography using (68)Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1501-1510. doi: 10.1007/s00259-017-3676-6
[10]	Zhang W, Wu P, Li F, et al. Potential Applications of Using ⁶⁸Ga-Evans Blue PET/CT in the Evaluation of Lymphatic Disorder: Preliminary Observations[J]. Clin Nucl Med, 2016, 41: 302-308. doi: 10.1097/RLU.0000000000001171
[11]	Hou G, Jiang Y, Xu W, et al. (68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study[J]. Orphanet J Rare Dis, 2021, 16: 279. doi: 10.1186/s13023-021-01895-1
[12]	Hou G, Hou B, Jiang Y, et al. ⁶⁸Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema[J]. Clin Nucl Med, 2019, 44: 439-445. doi: 10.1097/RLU.0000000000002584
[13]	Chen H, Tong X, Lang L, et al. Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography[J]. Theranostics, 2017, 7: 2363-2376. doi: 10.7150/thno.19898
[14]	Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S51-S61.
[15]	Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 66-74. doi: 10.2967/jnumed.117.202275
[16]	Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427
[17]	Tian R, Jacobson O, Niu G, et al. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy[J]. Theranostics, 2018, 8: 735-745. doi: 10.7150/thno.23491
[18]	Bandara N, Jacobson O, Mpoy C, et al. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent[J]. Bioconjug Chem, 2018, 29: 2448-2454. doi: 10.1021/acs.bioconjchem.8b00341
[19]	Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 1699-1705. doi: 10.2967/jnumed.118.209841
[20]	Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study[J]. Theranostics, 2018, 8: 3308-3316. doi: 10.7150/thno.25919
[21]	Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 947-957. doi: 10.1007/s00259-019-04530-1
[22]	Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. doi: 10.2967/jnumed.120.248658
[23]	Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 453-463. doi: 10.1007/s00259-015-3193-4
[24]	Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 1238-1246. doi: 10.1007/s00259-015-3041-6
[25]	Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with ¹⁷⁷Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 205-210. doi: 10.1007/s00259-013-2547-z
[26]	Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience[J]. Pancreas, 2014, 43: 518-525. doi: 10.1097/MPA.0000000000000113
[27]	Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 5-19. doi: 10.1007/s00259-014-2893-5
[28]	Paganelli G, Sansovini M, Ambrosetti A, et al. ¹⁷⁷Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 1845-1851. doi: 10.1007/s00259-014-2735-5
[29]	Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate[J]. J Nucl Med, 2013, 54: 1857-1861. doi: 10.2967/jnumed.112.119347
[30]	Jonathan S, Edward W, Beth C, et al. NETTER-1 Phase Ⅲ in Patients With Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-DOTATATE: Efficacy and Safety Results[J]. J Nucl Med, 2016, 57: 629.
[31]	Brieau B, Hentic O, Lebtahi R, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after ¹⁷⁷Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy[J]. Endocr Relat Cancer, 2016, 23: L17-L23. doi: 10.1530/ERC-15-0543
[32]	Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
[33]	Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J]. Hum Pathol, 2007, 38: 696-701. doi: 10.1016/j.humpath.2006.11.012
[34]	Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma[J]. Urol Oncol, 2009, 27: 525-528. doi: 10.1016/j.urolonc.2008.04.007
[35]	Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19: 715-718.
[36]	Weineisen M, Schottelius M, Simecek J, et al. ⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies[J]. J Nucl Med, 2015, 56: 1169-1176. doi: 10.2967/jnumed.115.158550
[37]	Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer[J]. J Nucl Med, 2015, 56: 914-920. doi: 10.2967/jnumed.114.147413
[38]	Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi: 10.1056/NEJMoa2107322
[39]	Wang Z, Jacobson O, Tian R, et al. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG[J]. Bioconjug Chem, 2018, 29: 2309-2315. doi: 10.1021/acs.bioconjchem.8b00292
[40]	Wang Z, Tian R, Niu G, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors[J]. Bioconjug Chem, 2018, 29: 3213-3221. doi: 10.1021/acs.bioconjchem.8b00556
[41]	Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. doi: 10.1007/s00259-018-4096-y
[42]	Zang J, Liu Q, Sui H, et al. (177)Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer[J]. J Nucl Med, 2020, 61: 1772-1778. doi: 10.2967/jnumed.120.242263
[43]	Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. doi: 10.1016/S1470-2045(18)30198-0

施引文献

资源附件(0)

访问统计

点击查看大图

图(1)

计量

文章访问数: 665
HTML全文浏览量: 171
PDF下载量: 102
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

doi: 10.12290/xhyxzz.2021-0764

通讯作者:
陈小元，E-mail：chen.shawn@nus.edu.sg

朱朝晖，E-mail：zhuzhh@pumch.cn

计量

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

Corresponding author: CHEN Xiaoyuan, E-mail: chen.shawn@nus.edu.sg; ZHU Zhaohui, E-mail: zhuzhh@pumch.cn

计量

目录

留言板

伊文思兰改造多肽用于诊疗一体化的临床转化研究进展

doi: 10.12290/xhyxzz.2021-0764

通讯作者: 陈小元，E-mail：chen.shawn@nus.edu.sg 朱朝晖，E-mail：zhuzhh@pumch.cn

计量

出版历程

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

Corresponding author: CHEN Xiaoyuan, E-mail: chen.shawn@nus.edu.sg; ZHU Zhaohui, E-mail: zhuzhh@pumch.cn

计量

出版历程

目录

通讯作者:
陈小元，E-mail：chen.shawn@nus.edu.sg

朱朝晖，E-mail：zhuzhh@pumch.cn